These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 22335056

  • 21. Use of combination therapy for dyslipidemia: a lipid clinic approach.
    Brown AS.
    Am J Cardiol; 2002 Nov 20; 90(10B):44K-49K. PubMed ID: 12467939
    [Abstract] [Full Text] [Related]

  • 22. Cholesterol drug controversy continues.
    Mitka M.
    JAMA; 2008 May 21; 299(19):2266. PubMed ID: 18492963
    [No Abstract] [Full Text] [Related]

  • 23. The ENHANCE trial.
    Porat G.
    Cleve Clin J Med; 2008 Nov 21; 75(11):763, 767; author reply 767. PubMed ID: 19086111
    [No Abstract] [Full Text] [Related]

  • 24. The ENHANCE trial.
    Fee WH.
    Cleve Clin J Med; 2008 Nov 21; 75(11):763; author reply 767. PubMed ID: 19068956
    [No Abstract] [Full Text] [Related]

  • 25. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Diamond GA, Kaul S.
    N Engl J Med; 2008 Jul 31; 359(5):530; author reply 532. PubMed ID: 18677796
    [No Abstract] [Full Text] [Related]

  • 26. Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
    Moon YS, Chun P, Chung S.
    Drugs Today (Barc); 2007 Jan 31; 43(1):35-45. PubMed ID: 17315051
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Connor WE.
    N Engl J Med; 2008 Jul 31; 359(5):530; author reply 532-3. PubMed ID: 18677797
    [No Abstract] [Full Text] [Related]

  • 31. Cholesterol lowering and ezetimibe.
    Drazen JM, Jarcho JA, Morrissey S, Curfman GD.
    N Engl J Med; 2008 Apr 03; 358(14):1507-8. PubMed ID: 18376001
    [No Abstract] [Full Text] [Related]

  • 32. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial: comment on Ruggenenti et al.
    Sarigianni M, Katsiki N, Mikhailidis DP.
    Diabetes Care; 2010 Oct 03; 33(10):e132; author reply e133. PubMed ID: 20876706
    [No Abstract] [Full Text] [Related]

  • 33. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.
    Am J Cardiol; 2010 Feb 15; 105(4):487-94. PubMed ID: 20152243
    [Abstract] [Full Text] [Related]

  • 34. Ezetimibe: a turbocharger for the race to reach NCEP LDL goals.
    Lee S.
    S D J Med; 2005 Oct 15; 58(10):435-6. PubMed ID: 16425945
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
    Molcányiová A, Stancáková A, Javorský M, Tkác I.
    Pharmacol Res; 2006 Sep 15; 54(3):203-7. PubMed ID: 16737822
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 15; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.